Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients

Figures & data

Table 1 Patients’ characteristics

	Number	%
Age group (years), median: 45 (range 24–78) years
<50	82	67.8
50–59	23	19.0
≥60	16	13.2
Histology
Infiltrating ductal	117	96.7
Infiltrating lobular	3	2.5
Clinical tumor size (cm), mean: 5.5 cm
≤2	6	5.0
2.1–4	39	32.2
>4	76	62.8
Gradea
I	2	1.7
II	47	38.8
III	69	57.0
Node status
Negative	27	22.3
Positive	94	77.7
Hormone receptors
ER positive	82	67.8
PR positive	75	62.0
ER and/or PR positive	88	72.7
ER and PR negative	33	27.2
Type of surgeryb
Mastectomy	93	76.9
BCS	26	21.5

Note:

a Three patients had unknown tumor grade;

b two patients did not undergo surgery.

Abbreviations: BCS, breast-conserving surgery; ER, estrogen receptor; PR, progesterone receptor.

Figure 1 pCR rate according to pretreatment characteristics.

Abbreviations: HR, hormone receptor; pCR, pathological complete response.

Figure 2 (A) Disease-free survival for all patients. (B) Disease-free survival by pCR.

Abbreviation: pCR, pathological complete response.

Figure 3 (A) Overall survival for all patients. (B) Overall survival by pCR.

Abbreviation: pCR, pathological complete response.